In summary, EBF1 exerts potent tumor-suppressive effects in GC by targeting both AKR1B1 and TERT (Figure 2), and restoring EBF1 expression represents a promising strategy for targeted therapy. The gene discussed is AKR1B1; the disease is neoplasm.